Related Experiment Video

Updated: Apr 30, 2026

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

4.2K

Sunitinib in the treatment of advanced solid tumors

Amal Imbulgoda1, Daniel Y C Heng, Christian Kollmannsberger

  • 1Medical Oncology, Tom Baker Cancer Center, Calgary, Canada.

Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer
|April 24, 2014
PubMed

Insights

Sunitinib effectively treats advanced renal cell carcinoma, gastrointestinal stromal tumors, and pancreatic neuroendocrine tumors by inhibiting multiple kinases. This review covers its development and pivotal trial results supporting its use.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Sunitinib is an oral multikinase inhibitor targeting key receptors like VEGFR, PDGFR, and c-kit.
  • Its efficacy is established in metastatic renal cell carcinoma (RCC), unresectable gastrointestinal stromal tumors (GIST), and pancreatic neuroendocrine tumors (PNET).

Purpose of the Study:

  • To review the preclinical data and pivotal phase III clinical trial results for sunitinib.
  • To support the widespread clinical application of sunitinib in specific advanced cancers.

Main Methods:

  • Review of preclinical studies investigating sunitinib's mechanism of action.
  • Analysis of data from pivotal phase III clinical trials in RCC, GIST, and PNET.

Main Results:

  • Sunitinib demonstrated significant efficacy in treating advanced RCC, GIST, and PNET.
  • Phase III trials confirmed sunitinib's survival benefits in these indications.
  • Common side effects such as hypertension and hand-foot syndrome were manageable.

Conclusions:

  • Sunitinib is a well-established and effective treatment for advanced RCC, GIST, and PNET.
  • The drug's targeted inhibition of multiple receptors underpins its therapeutic success.
  • Continued research may explore its utility in other tumor types.

More Related Videos

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-308:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.8K
Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma06:08

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

2.6K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.1K